Galectin Therapeutics (PHPN) Stock Statistics & Valuation Metrics
Total Valuation
Galectin Therapeutics has a market cap or net worth of EUR 299.80M. The enterprise value is EUR 432.36M.
- Market Cap
- EUR 299.80M
- Enterprise Value
- EUR 432.36M
Share Statistics
Galectin Therapeutics has 100,849,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 100,849,650
- Owned by Insiders
- 51.09%
- Owned by Institutions
- 8.44%
Financial Efficiency
Galectin Therapeutics’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is -174.29%.
- Return on Equity (ROE)
- 0.24
- Return on Assets (ROA)
- -1.58
- Return on Invested Capital (ROIC)
- -174.29%
- Return on Capital Employed (ROCE)
- -1.75
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.43M
- Employee Count
- 9
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Galectin Therapeutics is -7.78. Galectin Therapeutics’s PEG ratio is -0.20.
- PE Ratio
- -7.78
- PS Ratio
- 0.00
- PB Ratio
- -1.60
- Price to FCF
- -13.76
- Price to Operating Cash Flow
- -13.76
- PEG Ratio
- -0.20
Income Statement
In the last 12 months, Galectin Therapeutics had revenue of 0 and earned -30.84M in profits. Earnings per share was -0.48.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -20.09M
- Pretax Income
- -30.84M
- Net Income
- -30.84M
- EBITDA
- -23.45M
- Earnings Per Share (EPS)
- -0.48
Cash Flow
In the last 12 months, operating cash flow was -15.89M and capital expenditures 0, giving a free cash flow of -15.89M billion.
- Operating Cash Flow
- -15.89M
- Free Cash Flow
- -15.89M
- Free Cash Flow per Share
- -0.24
Dividends & Yields
Galectin Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.27%
- Earnings Yield
- -12.73%
Stock Price Statistics
- Beta
- -0.53
- 52-Week Price Change
- -33.02%
- 50-Day Moving Average
- 3.24
- 200-Day Moving Average
- 2.67
- Relative Strength Index (RSI)
- 41.76
- Average Volume (3m)
- ―
Important Dates
Galectin Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Galectin Therapeutics as a current ratio of 2.42, with Debt / Equity ratio of -105.99%
- Current Ratio
- 2.42
- Quick Ratio
- 2.42
- Debt to Market Cap
- 0.50
- Net Debt to EBITDA
- -4.95
- Interest Coverage Ratio
- -2.74
Taxes
In the past 12 months, Galectin Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Galectin Therapeutics EV to EBITDA ratio is -24.95, with an EV/FCF ratio of -21.59.
- EV to Sales
- 0.00
- EV to EBITDA
- -24.95
- EV to Free Cash Flow
- -21.59
- EV to Operating Cash Flow
- -21.59
Balance Sheet
Galectin Therapeutics has EUR 13.27M in cash and marketable securities with EUR 137.70M in debt, giving a net cash position of -EUR 124.43M billion.
- Cash & Marketable Securities
- EUR 13.27M
- Total Debt
- EUR 137.70M
- Net Cash
- -EUR 124.43M
- Net Cash Per Share
- -EUR 1.23
- Tangible Book Value Per Share
- -EUR 2.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Galectin Therapeutics is EUR 9.82, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 9.82
- Price Target Upside
- 245.82% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 37.95%
Scores
- Smart Score
- 6
- AI Score
- ―
